To gain insight into the effect of SGLT2 inhibitors on whole-body glucose homeostasis, we performed a hyperinsulinemic-euglycemic clamp test and an OGTT in individuals with type 2 diabetes who are treated with dapagliflozin. Here, SLC5A2 is linked to type 2 diabetes mellitus.